<DOC>
	<DOC>NCT00265993</DOC>
	<brief_summary>Study objectives : - To evaluate the efficacy/safety profile of enoxaparin once a day treatment in acute venous thromboembolic disease.</brief_summary>
	<brief_title>Enoxaparin in Acute Venous Thromboembolic Disease</brief_title>
	<detailed_description />
	<mesh_term>Thrombosis</mesh_term>
	<mesh_term>Venous Thrombosis</mesh_term>
	<mesh_term>Thromboembolism</mesh_term>
	<criteria>Patients with symptomatic lowerextremity deep venous thrombosis confirmed by doppler USG (ultrasonography), with or without confirmed symptomatic pulmonary embolism associated with provoked risk factors Patients with a history of heparin or warfarin treatment longer than 24 hours, Patients requiring thrombolytic treatment, Patients having thrombophilia diagnosis, Patients with prior deep vein thrombosis or pulmonary emboli evidence, Patients with familial bleeding disorder, Patients who are at any known bleeding risk, such as active bleeding, active ulcerative bowel disease, angiodysplasia and having oculary, spinal or central nervous system surgery within the last month Patients with renal failure (serum creatinine concentration &gt; 180 mmol/L or &gt; 2.03 mg/dL), Patients with severe hepatic failure Patients with history of allergy against heparin and protamine, Patients with history of thrombocytopenia associated with heparin administration or of skin necrosis after heparin or warfarin treatment, Patients participating in another clinical study within the last 4 months Patients who are pregnant The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2010</verification_date>
</DOC>